Isocitrate Dehydrogenase 1 (IDH1)

Isocitrate dehydrogenase 1 (IDH1) EC:1.1.1.42 is one of three isocitrate dehydrogenase isoforms found in humans. Mutated IDH1 catalyzes α-KG to D-2-hydroxyglutarate (D2HG) and has been linked to tumorigenesis in certain types of cancers.

Products

Background

Literature (4)

Gene Data

Isocitrate Dehydrogenase 1 (IDH1) Inhibitors
Cat. No.	Product Name / Activity
7087	AGI 5198
	Potent and selective inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1)
7761	Ivosidenib New
	Potent inhibitor of mutant isocitrate dehydrogenase (mIDH1)
Other
Cat. No.	Product Name / Activity
6124	(R)-2-Hydroxyglutaric acid disodium salt
	Oncometabolite produced by mutant isocitrate dehydrogenase

Related Targets

Epigenetics

Isocitrate dehydrogenase 1 (IDH1) EC:1.1.1.42 is one of three isocitrate dehydrogenase isoforms found in humans. IDH1 and IDH2 are homodimeric enzymes found in the cytoplasm and mitochondria, respectively. In their wildtype form, they catalyze the conversion of isocitrate to α-ketoglutarate (α-KG), an essential intermediate in the Krebs cycle. IDH1 and IDH2 are structurally and functionally similar, but they differ substantially from IDH3 (an enzyme that plays a role in the Krebs cycle production of NADH).

In hypoxic cancer cells, or in those with defects in the electron transport chain, HIF-1 mediates signaling that upregulates PDK1 and Myc. This in turn drives IDH1-mediated reductive metabolism of glutamine, a process that is integral to lipogenesis in cancer cells. Genome sequencing projects have identified that mutations in IDH1 are linked to glioblastomas and acute myeloid leukemias (AML), as well as other cancers. Mutant IDH1 converts α-KG to D-2-hydroxyglutarate (D2HG) resulting in high intracellular levels of D2HG, which have been postulated to act as an oncometabolite, driving tumorigenesis. D2HG competitively blocks α-KG binding at a family of enzymes called 2-OG-dependent dioxygenases, which are regulators of important epigenetic events. Mutant IDH enzymes are strongly associated with hypermethylation of CpG islands in AML and glioblastomas. Furthermore, mutations in IDH1 switch the enzyme's function from NADPH production to NADPH catabolism, thus reducing the prevalence of a critical redox mediator.

External sources of pharmacological information for Isocitrate Dehydrogenase 1 (IDH1) :

BJP Guide

Literature for Isocitrate Dehydrogenase 1 (IDH1)

Tocris offers the following scientific literature for Isocitrate Dehydrogenase 1 (IDH1) to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

Cancer Metabolism
Epigenetics in Cancer
Receptor Signaling
Cell Cycle and DNA Damage Repair
Angiogenesis
Invasion and Metastasis

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Cancer Metabolism PosterUpdated

This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.

Epigenetics in Cancer PosterUpdated

This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.